News >

OS Benefit Confirms Osimertinib as Frontline Standard in EGFR+ NSCLC

Kristi Rosa
Published: Thursday, Oct 10, 2019

Clarke A. Low, MD, director of thoracic oncology at Intermountain Healthcare

Clarke A. Low, MD

Overall survival (OS) from the phase III FLAURA trial have confirmed osimertinib (Tagrisso) as the new standard frontline treatment for patients with EGFR-mutated non–small cell lung cancer (NSCLC), said Clarke A. Low, MD, adding that the drug’s tolerability plus its central nervous system (CNS) activity sets it apart from other available TKIs.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Experts Weigh-In on Emerging Immune Checkpoint Inhibitors and Combination Strategies for Advanced NSCLCNov 30, 20191.5
Burst CME™ – Cancer Summaries and Commentaries: Update from Toronto: Advances in the Treatment of Lung CancersNov 30, 20190.5
Publication Bottom Border
Border Publication
x